Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00346164
Registration number
NCT00346164
Ethics application status
Date submitted
28/06/2006
Date registered
29/06/2006
Date last updated
28/04/2022
Titles & IDs
Public title
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Query!
Scientific title
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age
Query!
Secondary ID [1]
0
0
NCI-2009-00426
Query!
Secondary ID [2]
0
0
ARST0332
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Adult Alveolar Soft-part Sarcoma
0
0
Query!
Adult Angiosarcoma
0
0
Query!
Adult Epithelioid Sarcoma
0
0
Query!
Adult Extraskeletal Chondrosarcoma
0
0
Query!
Adult Extraskeletal Osteosarcoma
0
0
Query!
Adult Fibrosarcoma
0
0
Query!
Adult Leiomyosarcoma
0
0
Query!
Adult Liposarcoma
0
0
Query!
Adult Malignant Fibrous Histiocytoma
0
0
Query!
Adult Malignant Hemangiopericytoma
0
0
Query!
Adult Malignant Mesenchymoma
0
0
Query!
Adult Neurofibrosarcoma
0
0
Query!
Adult Synovial Sarcoma
0
0
Query!
Childhood Alveolar Soft-part Sarcoma
0
0
Query!
Childhood Angiosarcoma
0
0
Query!
Childhood Epithelioid Sarcoma
0
0
Query!
Childhood Fibrosarcoma
0
0
Query!
Childhood Leiomyosarcoma
0
0
Query!
Childhood Liposarcoma
0
0
Query!
Childhood Malignant Mesenchymoma
0
0
Query!
Childhood Neurofibrosarcoma
0
0
Query!
Childhood Synovial Sarcoma
0
0
Query!
Dermatofibrosarcoma Protuberans
0
0
Query!
Metastatic Childhood Soft Tissue Sarcoma
0
0
Query!
Nonmetastatic Childhood Soft Tissue Sarcoma
0
0
Query!
Stage I Adult Soft Tissue Sarcoma
0
0
Query!
Stage II Adult Soft Tissue Sarcoma
0
0
Query!
Stage III Adult Soft Tissue Sarcoma
0
0
Query!
Stage IV Adult Soft Tissue Sarcoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Sarcoma (also see 'Bone') - soft tissue
Query!
Cancer
0
0
0
0
Query!
Bone
Query!
Cancer
0
0
0
0
Query!
Children's - Other
Query!
Cancer
0
0
0
0
Query!
Any cancer
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - doxorubicin hydrochloride
Other interventions - clinical observation
Treatment: Surgery - therapeutic conventional surgery
Treatment: Other - 3-dimensional conformal radiation therapy
Treatment: Drugs - ifosfamide
Experimental: Arm A: No adjuvant treatment - Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor = 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).
Experimental: Arm B: Low risk; adjuvant radiotherapy - Patients with high-grade tumor = 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.
Experimental: Arm C: Intermediate & High risk; adjuvant chemoradiotherapy - High risk [metastatic, resected, incompletely resected, or unresected disease] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.
Experimental: Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy - High risk [metastatic, resected, incompletely resected, or unresected disease] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.
Treatment: Drugs: doxorubicin hydrochloride
Given IV
Other interventions: clinical observation
Patients undergo observation
Treatment: Surgery: therapeutic conventional surgery
Patients undergo surgery
Treatment: Other: 3-dimensional conformal radiation therapy
Patients undergo radiotherapy
Treatment: Drugs: ifosfamide
Given IV
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Intervention code [3]
0
0
Treatment: Surgery
Query!
Intervention code [4]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Probability for Event Free Survival.
Query!
Assessment method [1]
0
0
Probability of no relapse, secondary malignancy or death after 5 years since enrollment.
Query!
Timepoint [1]
0
0
5 years
Query!
Secondary outcome [1]
0
0
Toxicity Rate
Query!
Assessment method [1]
0
0
Percentage of Arm D patients experiencing grade 4+ adverse events.
Query!
Timepoint [1]
0
0
13 weeks
Query!
Secondary outcome [2]
0
0
Complete or Partial Response Rate
Query!
Assessment method [2]
0
0
Tumor response by imaging. Complete Response (CR): Complete disappearance of the tumor. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment. Overall Response (OR)=CR+PR.
Query!
Timepoint [2]
0
0
13 weeks
Query!
Secondary outcome [3]
0
0
Percent Tumor Necrosis
Query!
Assessment method [3]
0
0
Percent tumor necrosis by pathology review.
Query!
Timepoint [3]
0
0
13 weeks
Query!
Secondary outcome [4]
0
0
Event Free Survival Probability Disease Extent
Query!
Assessment method [4]
0
0
Probability of no relapse, secondary malignancy or death after 5 years since enrollment.
Query!
Timepoint [4]
0
0
5 years
Query!
Secondary outcome [5]
0
0
Event Free Survival Probability Histologic Grade
Query!
Assessment method [5]
0
0
Probability of no relapse, secondary malignancy or death after 5 years since enrollment
Query!
Timepoint [5]
0
0
5 years
Query!
Secondary outcome [6]
0
0
Overall Survival Probability Disease Extent
Query!
Assessment method [6]
0
0
Probability of survival after 5 years since enrollment.
Query!
Timepoint [6]
0
0
5 years
Query!
Secondary outcome [7]
0
0
Overall Survival Probability Extent of Resection of the Primary Tumor
Query!
Assessment method [7]
0
0
Probability of survival after 5 years since enrollment.
Query!
Timepoint [7]
0
0
5 years
Query!
Secondary outcome [8]
0
0
Incidence of Distant Metastasis
Query!
Assessment method [8]
0
0
Percent of patients who had distant metastasis.
Query!
Timepoint [8]
0
0
Up to 10 years
Query!
Secondary outcome [9]
0
0
Genetic and Gene Expression Profiles
Query!
Assessment method [9]
0
0
The tumors from patients registered on D9902 will be analyzed for genetic and gene expression profiles. The study will prospectively evaluate each tumor and confirm newly defined sarcoma diagnostic criteria based on cancer signatures in NRSTS.
Query!
Timepoint [9]
0
0
At diagnosis
Query!
Secondary outcome [10]
0
0
Degree of Agreement in Histologic Grade Determined by the Enrolling Institution Versus by Central Pathology Reviewers
Query!
Assessment method [10]
0
0
Histologic grades were determined by the central pathology reviewers and institutional pathologists based on published standards. A higher grade is associated with a more severe disease.
Query!
Timepoint [10]
0
0
At Diagnosis
Query!
Secondary outcome [11]
0
0
Degree of Agreement in Histologic Grade Between Pediatric Oncology Group (POG) and Fédération Nationale Des Centres de Lutte Contre le Cancer (FNCLCC) Pathologic Grading Systems
Query!
Assessment method [11]
0
0
POG and FNCLCC grades were determined by pathologists based on published standards. A higher grade is associated with a more severe disease.
Query!
Timepoint [11]
0
0
At diagnosis
Query!
Eligibility
Key inclusion criteria
- Newly diagnosed non-rhabdomyosarcoma soft tissue sarcoma (STS), confirmed by central
pathology review via concurrent enrollment on protocol COG-D9902
- Metastatic or non metastatic disease
- Meets 1 of the following criteria:
- Intermediate (i.e., rarely metastasizing) or malignant STS, including any of the
following:
- Adipocytic tumor, including liposarcoma of any of the following histology
subtypes:
- Dedifferentiated
- Myxoid
- Round cell
- Pleomorphic type
- Mixed-type
- Not otherwise specified (NOS)
- Fibroblastic/myofibroblastic tumors, including any of the following:
- Solitary fibrous tumor
- Hemangiopericytoma
- Low-grade myofibroblastic sarcoma
- Myxoinflammatory fibroblastic sarcoma
- Adult fibrosarcoma*
- Myxofibrosarcoma
- Low-grade fibromyxoid sarcoma or hyalinizing spindle-cell tumor
- Sclerosing epithelioid fibrosarcoma
- So-called fibrohistiocytic tumors, including any of the following:
- Plexiform fibrohistiocytic tumor
- Giant cell tumor of soft tissues
- Pleomorphic malignant fibrous histiocytoma (MFH)/undifferentiated
pleomorphic sarcoma
- Giant cell MFH/undifferentiated pleomorphic sarcoma with giant cells
- Inflammatory MFH/undifferentiated pleomorphic sarcoma with prominent
inflammation
- Smooth muscle tumor (leiomyosarcoma)
- Pericytic [perivascular] tumor (malignant glomus tumor or glomangiosarcoma)
- Vascular tumor, including angiosarcoma
- Chondro-osseous tumors of any of the following types:
- Mesenchymal chondrosarcoma
- Extraskeletal osteosarcoma
- Tumors of uncertain differentiation, including any of the following:
- Angiomatoid fibrous histiocytoma
- Ossifying fibromyxoid tumor
- Myoepithelioma/parachordoma
- Synovial sarcoma
- Epithelioid sarcoma
- Alveolar soft-part sarcoma
- Clear cell sarcoma of soft tissue
- Extraskeletal myxoid chondrosarcoma ("chordoid type")
- Malignant mesenchymoma
- Neoplasms with perivascular epithelioid cell differentiation (PEComa)
- Clear cell myomelanocytic tumor
- Intimal sarcoma
- Malignant peripheral nerve sheath tumor
- Dermatofibrosarcoma protuberans meeting both of the following criteria:
- Non metastatic disease
- Tumor must be grossly resected prior to study enrollment
- Embryonal sarcoma of the liver
- Unclassified STS that is too undifferentiated to be placed in a specific
pathologic category (undifferentiated STS or STS NOS)
- Gross resection of the primary tumor = 42 days prior to enrollment required except if
any of the following circumstances apply:
- Non metastatic high-grade tumor > 5 cm in maximal diameter and gross or
microscopic residual tumor is anticipated after resection
- Tumor of either high- or- low-grade that cannot be grossly excised without
unacceptable morbidity
- High-grade tumor with metastases
- Patients with metastatic low-grade tumor whose disease is amenable to gross
resection at all sites must undergo gross resection of all sites prior to
study entry
- Patients with a tumor recurrence after a gross total resection are not eligible
- Tumors arising in bone are not eligible
- Patients with epithelioid sarcoma, clear cell sarcoma, or clinical or radiologic
evidence of regional lymph node enlargement must undergo sentinel lymph node biopsies
or lymph node sampling to confirm the status of regional lymph nodes* NOTE: *Except in
cases where the study radiologist reviews the imaging and indicates that a biopsy is
not needed to confirm that the patient has lymph node involvement.
- If lymph node biopsies are positive for tumor (or the lymph nodes are classified
as positive by the study radiologist), formal lymph node dissection must be done
at the time of definitive surgery(prior to study entry for patients assigned to
study regimen C)
- Patients with metastatic disease must undergo a biopsy to confirm the presence of
metastatic tumor if all metastases are < 1 cm in maximal diameter (except in cases
where the study radiologist reviews the imaging and indicated that a biopsy is not
needed to confirm that the patient has metastatic disease)
- Lansky performance status (PS) 50-100% (for patients = 16 years of age) OR Karnofsky
PS 50-100% (for patients > 16 years of age)
- Life expectancy = 3 months
- Absolute neutrophil count = 1,000/mm³*
- Platelet count = 100,000/mm³*
- Creatinine clearance or radioisotope glomerular filtration rate = 70 mL/min (= 40
mL/min for infants < 1 year of age)* or serum creatinine based on age and/or gender as
follows:
- 0.4 mg/dL (1 month to < 6 months of age)
- 0.5 mg/dL (6 months to < 1 year of age)
- 0.6 mg/dL (1 year to < 2 years of age)
- 0.8 mg/dL (2 years to < 6 years of age)
- 1.0 mg/dL (6 years to < 10 years of age)
- 1.2 mg/dL (10 years to < 13 years of age)
- 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 years to < 16 years of age)
- 1.7 mg/dL (male) or 1.4 mg/dL (female) (= 16 years of age)
- Patients with urinary tract obstruction by tumor must meet the renal function criteria
listed above AND must have unimpeded urinary flow established via decompression of the
obstructed portion of the urinary tract
- Bilirubin = 1.5 times upper limit of normal (ULN)*
- Shortening fraction = 27% by echocardiogram* OR ejection fraction = 50% by
radionuclide angiogram*
- Not pregnant or nursing (patients undergoing radiotherapy and/or chemotherapy)
- No nursing for = 1 month after completion of study treatment in study regimens C
or D
- Fertile patients must use effective contraception during and for = 1 month after
completion of study treatment
- Negative pregnancy test
- No evidence of dyspnea at rest*
- No exercise intolerance*
- Resting pulse oximetry reading > 94% on room air (for patients with respiratory
symptoms)*
- Prior treatment for cancer allowed provided the patient meet the prior therapy
requirements
- No prior anthracycline (e.g., doxorubicin or daunorubicin) or ifosfamide chemotherapy
for patients enrolled on arm C or arm D
- No prior radiotherapy to tumor-involved sites
Query!
Minimum age
No limit
Query!
Query!
Maximum age
29
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/02/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
31/03/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
588
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Sydney Children's Hospital - Randwick
Query!
Recruitment hospital [2]
0
0
The Children's Hospital at Westmead - Sydney
Query!
Recruitment hospital [3]
0
0
Royal Brisbane and Women's Hospital - Herston
Query!
Recruitment hospital [4]
0
0
Women's and Children's Hospital-Adelaide - North Adelaide
Query!
Recruitment hospital [5]
0
0
Royal Children's Hospital - Parkville
Query!
Recruitment hospital [6]
0
0
Princess Margaret Hospital for Children - Perth
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
2145 - Sydney
Query!
Recruitment postcode(s) [3]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [4]
0
0
5006 - North Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3052 - Parkville
Query!
Recruitment postcode(s) [6]
0
0
6008 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Delaware
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
District of Columbia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Florida
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Georgia
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Hawaii
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Idaho
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Illinois
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Indiana
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Iowa
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Kentucky
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Louisiana
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Maine
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Maryland
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Massachusetts
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Michigan
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Minnesota
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Mississippi
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Missouri
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Nebraska
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Nevada
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
New Hampshire
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
New Jersey
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
New Mexico
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
New York
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
North Carolina
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
North Dakota
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Ohio
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Oklahoma
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Oregon
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Pennsylvania
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
Rhode Island
Query!
Country [38]
0
0
United States of America
Query!
State/province [38]
0
0
South Carolina
Query!
Country [39]
0
0
United States of America
Query!
State/province [39]
0
0
South Dakota
Query!
Country [40]
0
0
United States of America
Query!
State/province [40]
0
0
Tennessee
Query!
Country [41]
0
0
United States of America
Query!
State/province [41]
0
0
Texas
Query!
Country [42]
0
0
United States of America
Query!
State/province [42]
0
0
Utah
Query!
Country [43]
0
0
United States of America
Query!
State/province [43]
0
0
Vermont
Query!
Country [44]
0
0
United States of America
Query!
State/province [44]
0
0
Virginia
Query!
Country [45]
0
0
United States of America
Query!
State/province [45]
0
0
Washington
Query!
Country [46]
0
0
United States of America
Query!
State/province [46]
0
0
West Virginia
Query!
Country [47]
0
0
United States of America
Query!
State/province [47]
0
0
Wisconsin
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Alberta
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
British Columbia
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
Manitoba
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
Newfoundland and Labrador
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
Nova Scotia
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Ontario
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
Quebec
Query!
Country [55]
0
0
Canada
Query!
State/province [55]
0
0
Saskatchewan
Query!
Country [56]
0
0
New Zealand
Query!
State/province [56]
0
0
Auckland
Query!
Country [57]
0
0
Puerto Rico
Query!
State/province [57]
0
0
Santurce
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Children's Oncology Group
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Government body
Query!
Name [1]
0
0
National Cancer Institute (NCI)
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This phase III trial is studying observation to see how well a risk based treatment strategy
works in patients with soft tissue sarcoma. In the study, patients are assigned to receive
surgery +/- radiotherapy +/- chemotherapy depending on their risk of recurrence. Sometimes,
after surgery, the tumor may not need additional treatment until it progresses. In this case,
observation may be sufficient. Radiation therapy uses high-energy x-rays to kill tumor cells.
Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving chemotherapy and radiation therapy before surgery may make the tumor smaller
and reduce the amount of normal tissue that needs to be removed. Giving these treatments
after surgery may kill any tumor cells that remain after surgery.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00346164
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Sheri Spunt, MD
Query!
Address
0
0
Children's Oncology Group
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00346164
Download to PDF